Regeneron Pharma (REGN) Update Points to COVID Clinical Testing in Coming Weeks - Jefferies
Tweet Send to a Friend
Jefferies analyst Biren Amin reiterated a Buy rating and $657.00 price target on Regeneron Pharma (NASDAQ: REGN) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
